IP Library Granted Patent US 8,663,646
Granted Patent B2
US 8,663,646 · App. 12/592,815 · Granted Mar 4, 2014

P53 peptide vaccine

Inventors: Sjoerd Henricus van der Burg (Leiden, NL); Rienk Offringa (Leiden, NL); Cornelis Johannes Maria Melief (Haarlem, NL); Gemma G. Kenter (Amsterdam, NL)
Assignee: Academisch Ziekenhuis Leiden h.o.d.n. LUMC
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,663,646
App. No.
12/592,815
Granted
Mar 4, 2014
Kind
B2
Abstract

The invention relates to a peptide derived from p53 that could be used as a vaccine against cancer.

Claims (11)

1. A peptide composition comprising:

i) a peptide consisting of between 22 to 45 amino acids comprising between 22 to 30 contiguous amino acids from the amino acid sequence set forth in SEQ ID NO: 4,

ii) a peptide consisting of between 22 to 45 amino acids, comprising between 22 to 30 contiguous amino acids from the amino acid sequence set forth in SEQ ID NO: 5, and

iii) a peptide consisting of between 22 to 45 amino acids, comprising between 22 to 30 contiguous amino acids from the amino acid sequence set forth in SEQ ID NO: 15.

2. The peptide composition of claim 1 , further comprising a peptide consisting of between 22 to 45 amino acids, comprising between 22 to 30 contiguous amino acids from the amino acid sequence set forth in SEQ ID NO: 2, or a peptide consisting of between 22 to 45 amino acids, comprising between 22 to 30 contiguous amino acids from the amino acid sequence set forth in SEQ ID NO: 20.

3. A peptide composition according to claim 1 , comprising:

i) a peptide consisting of between 22 to 45 contiguous p53 amino acids, comprising between 22 to 30 contiguous amino acids from the amino acid sequence set forth in SEQ ID NO: 4,

ii) a peptide consisting of between 22 to 45 contiguous p53 amino acids, comprising between 22 to 30 contiguous amino acids from the amino acid sequence set forth in SEQ ID NO: 5; and

iii) a peptide consisting of between 22 to 45 contiguous p53 amino acids, comprising between 22 to 30 contiguous amino acids from the amino acid sequence set forth in SEQ ID NO: 15.

4. The peptide composition of claim 1 , 2 , or 3 further comprising a pharmaceutical excipient or an immune modulator.

5. The peptide composition according to claim 2 , further comprising a peptide consisting of between 22 to 45 contiguous p53 amino acids, comprising between 22 to 30 contiguous amino acids from the amino acid sequence set forth in SEQ ID NO: 2, or a peptide consisting of between 22 to 45 contiguous p53 amino acids, comprising between 22 to 30 contiguous amino acids from the amino acid sequence set forth in SEQ ID NO: 20.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 22, 2010
From: VAN DER BURG, SJOERD HENRICUS; OFFRINGA, RIENK; MELIEF, CORNELIS JOHANNES MARIA; KENTER, GEMMA G.
To: ACADEMISCH ZIEKENHUIS LEIDEN H.O.D.N. LUMC
Reel/Frame 023971/0520 →
Priority Claims (2)
EP 07109287 · May 31, 2007 · regional
EP 07109802 · Jun 7, 2007 · regional
Continuity (4)
Continuation PCTNL2008050319 · May 27, 2008
Provisional Application 60941070 · May 31, 2007
Provisional Application 60942483 · Jun 7, 2007
Related Publication 20100210529A1 · Aug 19, 2010